Macrogol Aurovitas (Macrogol 4000)

Macrogol Aurovitas is an oral osmotic laxative used to manage conditions related to impaired bowel motility.

• Constipation: Softens stool and promotes regular bowel movements in patients with functional constipation.
• Bowel preparation: Clears the intestinal tract before colonoscopy or other diagnostic procedures.
• Chronic idiopathic constipation: Provides long‑term relief for adults with persistent constipation.
• Faecal impaction: Helps to soften and evacuate hardened stool in cases of impaction.

• Macrogol 4000 acts as a high‑molecular‑weight polyethylene glycol that is poorly absorbed from the gastrointestinal tract. It creates an osmotic gradient that draws water into the lumen, increasing stool water content, reducing viscosity, and stimulating peristalsis to facilitate bowel evacuation.

Macrogol Aurovitas may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Abdominal bloating: Sensation of fullness or swelling in the abdomen.
• Nausea: Mild to moderate feeling of sickness.
• Flatulence: Increased intestinal gas.
• Diarrhea: Loose, watery stools.
• Electrolyte imbalance: Minor changes in serum electrolytes.
• Abdominal pain: Cramping or discomfort.

Serious or Rare Side Effects

• Severe dehydration: Marked loss of body fluids requiring medical attention.
• Allergic reaction: Rash, itching, swelling, or difficulty breathing.
• Severe abdominal pain: Persistent or worsening pain.
• Rectal bleeding: Unexplained blood in stool.
• Electrolyte disturbances: Significant hyponatremia or hypokalemia.
• Acute renal failure: Rare kidney impairment associated with excessive fluid loss.

When prescribing Macrogol Aurovitas, clinicians should consider several safety measures.

• Contraindication: Avoid use in patients with known or suspected bowel obstruction or perforation.
• Caution: Use carefully in individuals with inflammatory bowel disease during active flare-ups.
• Renal function: Monitor patients with impaired kidney function for signs of dehydration.
• Electrolytes: Check serum electrolytes in patients at risk of imbalance, especially the elderly.
• Pediatric use: Adjust dosing and monitor closely in children.
• Store at ambient temperature: Keep below 25°C, in the original packaging, protected from moisture and direct sunlight.

Macrogol Aurovitas can affect the absorption of other orally administered medicines.

Major Interactions (Avoid)

• Digoxin: Reduced absorption may decrease therapeutic effect.
• Lithium: Decreased lithium levels may lead to subtherapeutic concentrations.
• Antiepileptics: Potential reduction in drug plasma levels.

Moderate Interactions (Monitor Closely)

• Antacids: May alter the osmotic balance, affecting efficacy.
• Other laxatives: Combined use can increase risk of electrolyte disturbances.
• Diuretics: Concomitant use may exacerbate fluid loss and electrolyte imbalance.